Current treatment and management of infantile hemangiomas

Surv Ophthalmol. 2019 Sep-Oct;64(5):608-618. doi: 10.1016/j.survophthal.2019.02.005. Epub 2019 Feb 14.

Abstract

Infantile hemangiomas, otherwise known as infantile capillary hemangiomas, strawberry hemangiomas, or strawberry nevi, are nonmalignant vascular tumors that commonly affect children. The natural disease course typically involves growth for up to a year, followed by regression without treatment over a period of years with no cosmetic or functional sequelae. Less commonly, however, infantile hemangiomas can become a threat to vision or even life depending on location and size of the lesion. In addition, infantile hemangiomas, particularly those involving the face, may be disfiguring and result in lifelong sequelae. β-blockers have become a mainstay of therapy given their relatively low-risk profile and efficacy. Other treatment modalities previously described in the literature include corticosteroids (both intralesional and systemic), imiquimod, vincristine, bleomycin A5, and interferon α. More recently, angiotensin-converting enzyme inhibitors such as captopril have been used. Laser therapy and, less commonly, surgical excision are also available treatment options. We review current recommended management and treatment of capillary hemangiomas and discuss the benefits and risks of all previously reported treatment modalities.

Keywords: beta-blocker; capillary hemangioma; infantile hemangioma; propranolol; strawberry nevus; β-blocker.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Adrenergic beta-Antagonists / therapeutic use*
  • Disease Management*
  • Eye Neoplasms / therapy*
  • Hemangioma, Capillary / therapy*
  • Humans
  • Infant
  • Laser Therapy*
  • Neoplastic Syndromes, Hereditary / therapy*

Substances

  • Adrenal Cortex Hormones
  • Adrenergic beta-Antagonists

Supplementary concepts

  • Hemangioma, capillary infantile